The interplay of knowledge, motivation, and treatment response in medication adherence among patients with chronic myeloid leukemia treated with Imatinib

被引:0
|
作者
Omran, Mervat M. [1 ]
Ibrahim, Amel B. [2 ]
Abdelfattah, Raafat [3 ]
Moussa, Heba S. [4 ]
Shouman, Samia A. [1 ]
Hamza, Marwa S. [5 ]
机构
[1] Cairo Univ, NCI, Canc Biol Dept, Pharmacol Unit, Kasr Al Eini St, Cairo 11796, Egypt
[2] Zawia Univ, Fac Med, Dept Pharmacol, Az Zawiyah, Libya
[3] Cairo Univ, NCI, Med Oncol Dept, Cairo, Egypt
[4] Cairo Univ, NCI, Clin Pathol Dept, Cairo, Egypt
[5] British Univ Egypt, Fac Pharm, Clin Pharm Practice Dept, El Sherouk City, Cairo, Egypt
关键词
Imatinib mesylate; CML; adherence; trough; peak; CHRONIC MYELOGENOUS LEUKEMIA; CYTOGENETIC RESPONSES; TYROSINE KINASE; BLAST CRISIS; THERAPY; NONADHERENCE; OUTCOMES;
D O I
10.1080/10428194.2024.2403671
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chronic Myeloid Leukemia (CML) requires consistent medication adherence to Imatinib (IM) for optimal outcomes, however, adherence to oral chemotherapy is challenging. This observational study explores the relationship between patient knowledge, motivation, and adherence to IM therapy, and their collective impact on clinical outcomes. A prospective, observational study was conducted with 101 CML patients. The 6-Item Morisky Medication Adherence Scale (MMAS-6) was used to assess adherence, motivation, and knowledge levels. The study found that high motivation was significantly associated with lower BCR-ABL expression (p = 0.025). Patients with high knowledge and motivation had a 71% favorable response rate, compared to 0% in those with low knowledge and motivation (p = 0.01). As conclusion both patient motivation and knowledge are crucial for favorable treatment outcomes in CML. High levels of both significantly correlate with better clinical responses. Tailored interventions to enhance patient knowledge and motivation are essential.
引用
收藏
页码:123 / 130
页数:8
相关论文
共 50 条
  • [1] Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia
    Anderson, Kristin R.
    Chambers, Carole R.
    Lam, Nadine
    Yau, Patrick S.
    Cusano, Frances
    Savoie, M. Lynn
    Sheikh, Naureen
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2015, 21 (01) : 19 - 25
  • [2] Pregnancy among patients with chronic myeloid leukemia treated with imatinib
    Ault, P
    Kantarjian, H
    O'Brien, S
    Faderl, S
    Beran, M
    Rios, MB
    Koller, C
    Giles, F
    Keating, M
    Talpaz, M
    Cortes, J
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) : 1204 - 1208
  • [3] Predictors of Treatment Non-Adherence in Patients Treated with Imatinib Mesylate for Chronic Myeloid Leukemia
    StCharles, Meaghan
    Bollu, Vamsi K.
    Hornyak, Elizabeth
    Coombs, John
    Blanchette, Christopher M.
    DeAngelo, Daniel J.
    BLOOD, 2009, 114 (22) : 870 - 870
  • [4] Initiation of generic imatinib may improve medication adherence for patients with chronic myeloid leukemia
    Cole, Ashley L.
    Jazowski, Shelley A.
    Dusetzina, Stacie B.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 (11) : 1529 - 1533
  • [5] Monitoring response and treatment outcome in patients with chronic phase chronic myeloid leukemia (CML) treated with imatinib
    Teitelbaum, A.
    Spencer, D.
    Bollu, V. K.
    Chastek, B.
    Coombs, J.
    Kulakodlu, M.
    Morlock, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Medication Adherence to Tyrosine Kinase Inhibitors: 2-Year Analysis of Medication Adherence to Imatinib Treatment for Chronic Myeloid Leukemia and Correlation with the Depth of Molecular Response
    Santoleri, Fiorenzo
    Lasala, Ruggero
    Ranucci, Elena
    La Barba, Gaetano
    Di Lorenzo, Roberto
    Vetro, Antonio
    Di Bartolomeo, Paolo
    Costantini, Alberto
    ACTA HAEMATOLOGICA, 2016, 136 (01) : 45 - 51
  • [7] Pregnancy in patients with chronic myeloid leukemia treated with imatinib
    Yilmaz, Mehmet
    Demirhan, Osman
    Kucukosmanoglu, Ercan
    Pehlivan, Mustafa
    Okan, Vahap
    Balat, Ozcan
    Pehlivan, Sacide
    LEUKEMIA & LYMPHOMA, 2007, 48 (12) : 2454 - 2456
  • [8] LONG TERM MOLECULAR RESPONSE IN IMATINIB TREATED CHRONIC MYELOID LEUKEMIA PATIENTS
    Jovanovic, V.
    Bogdanovic, D.
    Djordjevic, A.
    Dencic-Fekete, S.
    Gotic, D.
    HAEMATOLOGICA, 2012, 97 : 542 - 542
  • [9] Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib
    McLean, LA
    Gathmann, I
    Capdeville, R
    Polymeropoulos, MH
    Dressman, M
    CLINICAL CANCER RESEARCH, 2004, 10 (01) : 155 - 165
  • [10] Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia
    Alves, Alexandra Rodrigues
    Lima, William Gustavo
    Nagai, Michelly Martins
    Vilela Rodrigues, Joao Paulo
    Ayres, Lorena Rocha
    BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 52 (04) : 581 - 589